Alkermes Phase III study spell good news for major depressive disorder space, says analyst

9 November 2016

Positive top-line results were announced last month by Ireland-headquartered Alkermes (Nasdaq: ALKS) for its Phase III study of ALKS-5461 as an adjunctive therapy for major depressive disorder (MDD), says analyst.

As explored in research and consulting firm GlobalData’s most recent MDD report, ALKS-5461 is one of six late-stage pipeline products showing promise with regards to improving efficacy and safety in the treatment of patients with the disorder. In October 2013, ALKS-5461 was granted fast track designation by the Food and Drug Administration for the adjunctive treatment of MDD in patients with an inadequate response to standard antidepressant therapies.

Christos Michaelides, GlobalData's analyst covering neurology and ophthalmology, explains: “This status will both facilitate and expedite the FDA developmental and regulatory review process for ALKS-5461, which GlobalData anticipates will enter the US market in early 2018”.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK